drugset / Trial / NCT05331014

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

NCT05331014 ↗

Phase 3 Completed 155 enrolled JW Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

Timeline

Start
2021-11-15
Primary completion
2022-11-08
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator LivaloV Unknown — Oral
Subject LivaloVA Unknown — Oral
Comparator VA Unknown — Oral